Acrux Limited (ASX: ACR), the Australian pharmaceutical company which specialises in administering drugs through the skin, today announced positive results from two more clinical studies of its Testosterone MD-Lotion® treatment for testosterone deficiency in men, which is associated with a number of symptoms including lethargy, depression and reduced libido. Both studies were conducted at the Centre for Clinical Studies, Melbourne, with Professor Susan Davis supervising as Principal Investigator. The studies compared blood levels of testosterone in healthy volunteers. The aim of the first study was to compare two different formulations of Testosterone MD Lotion®, and the aim of the second study was to compare two different application sites. The results of the first study showed that both formulations provided similar blood levels, providing options for continued development of either formulation. In the second study, there was a significant difference in absorption between the two different application sites, providing important information for the design of the remaining clinical studies in men. In both studies, the lotion was well tolerated, with no application site reactions noted, and no serious adverse events recorded. Full details of the studies are presented in Appendix 1. Acrux’s development of Testosterone MD Lotion® is continuing, with further studies to commence shortly to confirm the doses required to maintain testosterone blood levels in the target range for effective treatment.
